ArticleClinics (Sao Paulo, Brazil)2026
Association of blood urea nitrogen to high-density lipoprotein ratio with all-cause and cardiovascular mortality in individuals with mildly reduced eGFR.
Article in Clinics (Sao Paulo, Brazil), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with mild-to-moderate renal impairment face elevated cardiovascular risk, yet early detection tools remain limited. The Cardiovascular-Kidney-Metabolism (CKM) interplay underscores the need for integrated biomarkers. The Blood Urea Nitrogen (BUN) to High-Density Lipoprotein (HDL) cholesterol ratio (BUN/HDL) was therefore evaluated for early risk stratification.
methodsThis cohort study included National Health and Nutrition Examination Survey (NHANES) participants (2007‒2018) with mildly reduced estimated Glomerular Filtration Rate ([eGFR] < 90 mL/min/1.73 m
resultsElevated BUN/HDL showed a modest association with all-cause (HR = 1.050, 95% CI: 1.021-1.081) and cardiovascular mortality (HR = 1.062, 95% CI: 1.020‒1.105). Optimal cut-points were 6.41 (AUC = 0.650) for all-cause and 5.00 (AUC = 0.682) for cardiovascular mortality. Subgroup analyses suggested a stage-dependent pattern. For all-cause mortality, associations were consistent in Chronic Kidney Disease (CKD) stage G2 (HR = 1.079, p = 0.002) and G3 (HR = 1.058, p = 0.025). For cardiovascular mortality, the association was significant in CKD stage G2 (HR = 1.127, p < 0.001). This cardiovascular association was stronger in non-hypertensive individuals. Machine learning confirmed BUN/HDL as a robust predictor within NHANES dataset, with final models showing excellent discrimination (AUCs 0.820-0.837) and calibration.
conclusionThe BUN/HDL ratio demonstrates a consistent, albeit modest, association with mid-term mortality, providing preliminary support as a CKM risk indicator among individuals with mildly reduced eGFR.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.